The US FDA’s EIR is received for the drug-device combination to be commercialised from the Stelis Pharma#39;s flagship facility in Bengaluru, Indiafrom Moneycontrol Business News https://ift.tt/yiOkfgA
Tuesday, January 17, 2023
Subscribe to:
Post Comments (Atom)
LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally
A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...
-
In a regulatory filing the company said the Odisha Electricity Regulatory Commission (OERC) has awarded the Letter of Intent (LOI) to Tata ...
-
A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...
No comments:
Post a Comment